RNA, U1 small nuclear 104, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU1-104P profile across patient tissues and cancer cell-line models. RNU1-104P expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RNU1-104P is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, RNU1-104P RNA expression shows 8,972 significant gene co-expression associations, with the highest sampling consensus in LUSC. Together, these results highlight BRCA, STAD, and LUSC as cancer lineages where RNU1-104P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-104P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-104P survival associations across molecular data types. RNU1-104P RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-104P RNA expression–survival associations across cancer types. High RNU1-104P expression shows unfavorable associations in BRCA, LUSC, SARC, LIHC, PRAD and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for RNU1-104P RNA expression.
This table summarizes RNU1-104P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-104P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-104P shows higher tumor expression in STAD. The STAD box plot shows higher RNU1-104P RNA expression in tumor versus normal tissue (log2 FC = +0.078, t-test p = .015).
This table shows molecular features associated with RNU1-104P in patient tissues and cancer cell lines. In patient samples, RNU1-104P shows the broadest associations at the RNA and protein expression levels, with LUSC recurring as the lineage with the largest associated feature set.
